BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//6.6.4.4//EN
TZID:Europe/Berlin
X-WR-TIMEZONE:Europe/Berlin
BEGIN:VEVENT
UID:47@ditec-dus.de
DTSTART;TZID=Europe/Berlin:20250522T102500
DTEND;TZID=Europe/Berlin:20250522T150000
DTSTAMP:20250327T112426Z
URL:https://ditec-dus.de/events/symposium-innovations-in-fatty-liver-resea
 rch-and-therapy/
SUMMARY:Symposium: Innovations in fatty liver research and therapy
DESCRIPTION:Liver fibrosis • biomarker • drug development\nThe prevalen
 ce of fatty liver disease mirrors the global burden of the metabolic syndr
 ome\, while numbers alarmingly continuing to rise. Understanding the under
 lying disease mechanisms with cutting-edge human models\, refining targete
 d biomarker analysis\, and discovering innovative drug targets are key for
  the development of effective therapies.\nProgram:\n10.25 – 10.30 Welcom
 e \nLife Science Net Düsseldorf\, BioCologne\n10.30 – 10.40 Introductio
 n \nProf. Dr. Juergen Eckel\, CEO\, CMR CureDiab | Metabolic Research GmbH
 \, Düsseldorf\n10.40 – 11.00 Hepatic energy metabolism in steatotic liv
 er diseases: mechanisms and therapeutic targets\nDr. Bedair Dewidar\, Post
 doctoral Researcher\, German Diabetes Center\, Düsseldorf\n11.00 – 11.2
 0 Immunometabolic profiles of tissue-resident and monocyte-derived hepatic
  macrophage subsets during MASLD development\nDr. Bruno Guigas\, Associate
  Professor\, Leiden University Medical Center\, Leiden\, NL\n11.20 – 11.
 40 The development of a liver-chip for detection of drug-induced liver inj
 ury and fatty liver disease\nDr. Lorna Ewart\, CSO\, Emulate Inc. Boston\,
  US\n11.40 – 12.00 FibroPaths liver: combinatorial approach of in silico
 \, 2D and 3D ex vivo methods for the identification of novel therapeutic t
 argets in human liver diseases\nPD. Dr. Jan Fiedler\, Group Leader Molecul
 ar Biomarkers for Disease Modelling\, Fraunhofer Institute for Toxicology 
 and Experimental Medicine\, Hannover\nLunch Break\n13.00 – 13.20 The use
  of artificial intelligence for the analysis of histological imaging data\
 nDr. Tobias Seraphin\, Clinical Scientist &amp\; Resident\, Department of 
 Gastroenterology\, Hepatology\, and Infectious Diseases\, Düsseldorf Univ
 ersity Hospital\, Düsseldorf\n13.20 – 13.40 Dissecting Fibrotic Pathway
 s: the extra-cellular matrix as a driver and target\nProf. Dr. Gerhard Sen
 gle\, Group Leader Department of Pediatric and Adolescent Medicine\, Unive
 rsity Hospital\, Center for Molecular Medicine Cologne\n\n13.40 – 14.00 
 From bench to bedside and back to the future: lifecycle of pre-clinical an
 d clinical liver fibrosis biomarkers\nDr. Dimitar Tasev\, CSO\, GBS\, Leid
 en\n\nCoffee Break\n\n14.20 – 14.40 Role of Sema3A in early MASLD\nProf.
  Dr. Eckhard Lammert\, Head of Institute of Metabolic Physiology\, Heinric
 h Heine University\, Düsseldorf\n14.40 – 15.00 New MASLD drugs\nProf. D
 r. Juergen Eckel\, CEO\, CMR CureDiab Metabolic Research\, Düsseldorf\n15
 .00 Networking\nDownload Flyer zum Symposium
ATTACH;FMTTYPE=image/jpeg:https://ditec-dus.de/wp-content/uploads/2025/03/
 RZ-Bild_Mailing_Symposium_Rheinland_1100x600_03-2025.jpg
CATEGORIES:LifeScience-Veranstaltung
LOCATION:Life Science Center\, Merowingerplatz 1\, Düsseldorf\, 40225\, De
 utschland
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Merowingerplatz 1\, Düssel
 dorf\, 40225\, Deutschland;X-APPLE-RADIUS=100;X-TITLE=Life Science Center:
 geo:0,0
END:VEVENT
BEGIN:VTIMEZONE
TZID:Europe/Berlin
X-LIC-LOCATION:Europe/Berlin
BEGIN:DAYLIGHT
DTSTART:20250330T030000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
END:DAYLIGHT
END:VTIMEZONE
END:VCALENDAR